The present disclosure relates to an aromatic ring compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to an aromatic ring compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, particularly a use as a Nav inhibitor, and a use thereof in the preparation of a medicament for treating and/or alleviating pain and pain-related disorders. The groups in general formula (I) are as defined in the description.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
2.
NORBORNANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
The present disclosure relates to a norbornene derivative and a pharmaceutical use thereof. Specifically, the present disclosure relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for treating cardiovascular and cerebrovascular diseases.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
3.
PHARMACEUTICALLY ACCEPTABLE SALT OF DIHYDROPYRIDOPYRIMIDINE DERIVATIVE, AND CRYSTAL FORM AND USE THEREOF
The present disclosure relates to a pharmaceutically acceptable salt of a dihydropyridopyrimidine derivative, and a crystal form and the use thereof. Specifically, provided in the present disclosure are a pharmaceutically acceptable salt of (R)-N-((S)-2-(hexadeuterated dimethylamino)-1-phenylethyl)-6-methyl-2-(((1-methyl-1H-pyrazol-3-yl)-methyl)amino)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxamide, and a crystal form thereof and a preparation method therefor. The corresponding crystal form has a good stability and can be better used in clinical treatment.
The present disclosure relates to a dihydrofuro[3,4-f]quinazoline compound, a preparation method therefor and a use thereof in medicine. Specifically, the present disclosure relates to a dihydrofuro[3,4-f]quinazoline compound represented by formula (1), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a therapeutic agent, particularly a use of the compound in preparation of a drug for inhibiting KRAS amplification and/or mutant activity.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present disclosure relates to an amino-substituted heteroaromatic cyclic compound, a preparation method therefor, and the use thereof in medicine. Specifically, the present disclosure relates to an amino-substituted heteroaromatic cyclic compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, the use thereof as a therapeutic agent, particularly as a TYK2 inhibitor and/or a degradation agent, and the use thereof in the preparation of a drug for treating and/or preventing TYK2-mediated or -dependent diseases or disorders.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Provided is a method for treating a TSLP-associated inflammatory disease (e.g., nasal polyp and/or sinusitis) using an anti-TSLP antibody or an antigen-binding fragment thereof and pharmaceutical use.
The present disclosure relates to a benzene ring derivative and a pharmaceutical use thereof. In particular, the present disclosure relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The definition on substituents is as stated in the description.
The present disclosure relates to a protein containing a T cell receptor constant region and the medical use thereof. Specifically, the present disclosure relates to a modified T cell receptor (TCR) constant region, a protein containing the TCR constant region, a coding nucleic acid, a vector, a cell, a pharmaceutical composition, and the use thereof.
Provided is a preparation method for a selective estrogen receptor degrader. Specifically provided is a preparation method for a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. The method reduces the reaction steps, improves the reaction yield, and is suitable for industrial production.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07C 217/54 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
C07C 215/46 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
10.
ANTI-CLDN6 ANTIBODY, ANTIBODY-DRUG CONJUGATE COMPRISING SAME AND MEDICAL USE THEREOF
The present disclosure relates to an anti-CLDN6 antibody, an antibody-drug conjugate comprising same and a medical use thereof. Specifically, the present disclosure relates to an antibody-drug conjugate or a pharmaceutically acceptable salt thereof, which is an antibody-drug conjugate represented by general formula (IM) or a pharmaceutically acceptable salt thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
An anti-Nectin-4 antibody-drug conjugate for treating a tumor, and a method and medical use for treating a tumor with the anti-Nectin-4 antibody-drug conjugate.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates to a PD-1 binding protein and the pharmaceutical use. Specifically, the present disclosure relates to an anti-PD-1 antibody, a pharmaceutical composition containing the antibody, a method for treating inflammatory or autoimmune diseases, and the pharmaceutical use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to use of an anti-ANGPTL3 antibody in treating hyperlipidemia and a method. Specifically, the present invention relates to use of an anti-ANGPTL3 antibody or an antigen-binding fragment thereof in preparing a drug for treating hyperlipemia patients, wherein the hyperlipemia patients are subject to the risk of atherosclerosis cardiovascular disease.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention provides a use of an Eribulin derivative drug conjugate in the treatment of a tumor. Particularly, the present invention provides a use of a compound as represented by formula IA or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating a tumor disease resistant to an anti-HER2 antibody-drug conjugate.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
The present disclosure relates to a crystalline form of a pyridine-N-oxide derivative and a preparation method therefor. Specifically, provided in the present disclosure are crystal form A, crystal form B, crystal form C, crystal form D and crystal form E of a 4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-formamido)-2-((Z)-N'-hydroxycarbamimidoyl)pyridine1-oxide. The crystal forms have good stability and can be better used in clinical treatment.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present disclosure relates to a method for preparing a sulfonylurea derivative. Specifically, the present disclosure relates to a method for preparing a compound represented by formula (I), comprising the step of preparing the compound represented by formula (I) from a compound represented by formula (II) in the presence of LiOtBu. The method has a high yield and mild reaction conditions and thus is suitable for industrial production.
C07C 303/40 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
C07C 311/57 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
C07C 311/59 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
Provided are an amylin analogue and a pharmaceutical use thereof. Provided are a compound or a pharmaceutically acceptable salt thereof, an amylin analogue comprising the compound, a pharmaceutical composition and a pharmaceutical use thereof. The amylin analogue is a polypeptide analogue derived from pramlintide, has an agonist effect on a human amylin receptor and a human calcitonin receptor, and can be used for treatment of metabolic diseases such as obesity and diabetes.
A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
18.
METHOD FOR PREPARING BENZODIOXANE OR SALTS THEREOF
The present disclosure relates to a method for preparing a benzodioxane or salts thereof. Specifically, the method of the present disclosure comprises a step of reacting a compound of formula E under the presence of a tri-substituted phosphine/azodicarboxylate to form a compound of formula F.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
19.
ANTI-CD79B ANTIBODY-DRUG CONJUGATE COMBINED WITH IMMUNOTHERAPEUTIC AGENT AND CHEMOTHERAPEUTIC AGENT FOR TREATING TUMOR
The present invention relates to an anti-CD79b antibody-drug conjugate combined with an immunotherapeutic agent and a chemotherapeutic agent for treating a tumor, and in particular to a use of the anti-CD79b antibody-drug conjugate combined with the immunotherapeutic agent and/or the chemotherapeutic agent in the preparation of a drug for treating a tumor.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates to a pharmaceutical composition comprising a selective estrogen receptor degrader, and a preparation method therefor. Specifically, the present disclosure provides a composition, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and a filler, wherein the filler comprises microcrystalline cellulose and anhydrous dibasic calcium phosphate. The composition has good dissolution and stability.
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
The present disclosure relates to a pharmaceutically acceptable salt of a G12D inhibitor compound and a crystal form thereof. Specifically, provided in the present disclosure are a salt of 2-amino-4-((5S,5aS,6S,9R)-12-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-1-fluoro-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]cyclohepten-2-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and a crystal form thereof.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The present invention relates to a crystal form of a G12D inhibitor compound and a preparation method. Specifically, the present invention provides a crystal form of 2-amino-4-((5S,5aS,6S,9R)-12-((1-((4-(difluoromethylidenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-1-fluoro-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalen-2-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile, and a preparation method.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Disclosed are a GLP-1R agonist pharmaceutical composition and a use thereof. The pharmaceutical composition comprises a compound represented by formula I, or a pharmaceutically acceptable salt thereof, as an active ingredient. The pharmaceutical composition contains an acid-resistant compound, and can slowly release active ingredients in the pharmaceutical composition, so as to reduce side effects of in vivo absorption after GLP-1R administration.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The present disclosure relates to a quaternary ammonium compound and a pharmaceutical use thereof. Specifically, the present disclosure relates to a compound represented by formula IA or a pharmaceutically acceptable salt thereof, each substituent being as defined in the description.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
26.
CRYSTAL OF NITROGEN-BRIDGED HETEROCYCLIC COMPOUND AND PREPRATION METHOD THEREFOR
The present invention relates to a crystal of a nitrogen-bridged heterocyclic compound and a preparation method therefor. Specifically, the present invention relates to a crystal form of a fumarate of a compound represented by formula (I). The crystal provided by the present invention has excellent flowability, and is better for use in production and clinical treatment.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/00 - Drugs for disorders of the urinary system
An antibody-polypeptide conjugate and pharmaceutical use thereof. Specifically, the present invention relates to an antibody-polypeptide conjugate or a pharmaceutically acceptable salt thereof and pharmaceutical use thereof.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
28.
PHOSPHATE COMPOUND OF SUBSTITUTED PYRAZOLINE AZO DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
A phosphate compound of a substituted pyrazoline azo derivative or a pharmaceutically acceptable salt thereof. Specifically, provided are a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has good pharmacokinetic properties, and is beneficial to preparation of formulation forms having better patient compliance.
C07D 231/08 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
C07D 231/46 - Oxygen atom in position 3 or 5 and nitrogen atom in position 4
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
The present disclosure relates to tetrahydroisoquinoline and a pharmaceutical use thereof. Specifically, the present disclosure relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The definition of each substituent is as defined in the description.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
30.
PHARMACEUTICAL COMPOSITION COMPRISING BISPECIFIC ANTIBODY SPECIFICALLY BINDING DLL3 AND CD3
Provided is a pharmaceutical composition comprising a bispecific antibody specifically binding DLL3 and CD3. Specifically, provided is a pharmaceutical composition, comprising a bispecific antibody specifically binding DLL3 and CD3 and a buffering agent.
The present disclosure relates to an olefin compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to an olefin compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the olefin compound, and a use thereof as a therapeutic agent, in particular, a use thereof as an IL-17 inhibitor and a use thereof in the preparation of a drug for treating and/or preventing cancer, inflammation or autoimmune diseases, each group in general formula (I) being as defined in the description.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention provides an antibody specifically binding to CD3, a pharmaceutical composition containing the antibody, a preparation method for the antibody, and a use of the antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A method for treating metabolic diseases and pharmaceutical use of a GLP-1 analogue. Specifically, the present invention relates to a method for preventing or treating metabolic diseases, comprising administering the GLP-1 analogue or a pharmaceutically acceptable salt thereof once a week.
The present disclosure relates to a heterocyclic compound, and a preparation method therefor and a use thereof in medicine. In particular, the present disclosure relates to a heterocyclic compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, particularly as a GLP-1 receptor agonist. The definition of each group in the general formula (I) is as stated in the description.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The present disclosure relates to a method for preparing a heterologous multimer by means of a recombination reaction. In particular, the present disclosure relates to a method for preparing the heterologous multimer (especially a multispecific antibody), and changing the amino acid of the CH3 domain to facilitate the formation of the heterologous multimer (especially the multispecific antibody).
A method for treat tumors with an anti-HER3 antibody drug conjugate and an anti-VEGF antibody. In particular, the present invention relates to the use of an anti-HER3 antibody drug conjugate in combination with a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors and the use of a combination of an anti-HER3 antibody drug conjugate and a VEGF signaling pathway inhibitor in the preparation of a drug for treating tumors.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
The present disclosure relates to TRGV9 binding proteins and the medical use thereof. Specifically, the present disclosure relates to a TRGV9 binding protein, a GPC3/TRGV9 binding protein, a method for treating cancer using same, and the pharmaceutical use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure relates to a fused heteroaryl compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to a fused heteroaryl compound represented by general formula (I'), a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof as a therapeutic agent, especially a use thereof in the preparation of a medicament for inhibiting KRAS amplification and/or mutant activity. Each group in general formula (I') is as defined in the description.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present disclosure provides a pharmaceutical composition of a sulfonylurea derivative. Specifically, the present disclosure provides a pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, and a buffering agent. The composition has excellent stability. =
The present invention relates to a pharmaceutical composition comprising an anti-TSLP antibody and a use thereof. Specifically, the present invention relates to a pharmaceutical composition comprising an anti-TSLP antibody, a surfactant and an excipient, and a use thereof for treating TSLP-related diseases or disorders.
The present disclosure relates to amide-substituted cycloalkyl compounds, a preparation method therefor and the medical uses thereof. Specifically, the present disclosure relates to amide-substituted cycloalkyl compounds represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and the uses thereof as a therapeutic agent, in particular, the use thereof as an RXFP1 modulator and the use thereof in the preparation of drugs for treating and/or preventing RXFP1-mediated or dependent diseases or disorders.
C07C 237/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
C07C 61/35 - Unsaturated compounds having unsaturation outside the rings
C07C 51/09 - Preparation of carboxylic acids or their salts, halides, or anhydrides from carboxylic acid esters or lactones
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
42.
HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
The present disclosure relates to a heterocyclic compound, a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a heterocyclic compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, in particular, a use thereof as a Nav inhibitor and a use thereof in preparation of a drug for treating and/or relieving pain or pain-related diseases. Each group in the general formula (I) is as defined in the description.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
43.
PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF QUINAZOLINE DERIVATIVE, AND USE THEREOF
The present disclosure relates to a pharmaceutically acceptable salt and a crystalline form of a quinazoline derivative, and use thereof. Specifically, provided are a pharmaceutically acceptable salt of, a crystal form of, and a preparation method for 1-(endo-3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-fluoro-3-methylphenyl)amino)quinazolin-6-yl)oxy)-8-azabicyclo[3.2.1]oct-8-yl)prop-2-en-1-one; the corresponding salt has good stability and can be better used in clinical treatment.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A crystalline form of a quinazoline derivative and a preparation method therefor. Specifically, provided is an E crystal form, D crystal form, and H crystal form of 1-(endo-3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-fluoro-3-methylphenyl)amino)quinazolin-6-yl)oxy)-8-azabicyclo[3.2.1]oct-8-yl)prop-2-en-1-one, which have good stability and can be better used for clinical treatment. Formula (I).
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present disclosure relates to a use of an anti-HER3 antibody-drug conjugate in treating tumors and a method for treating tumors using the anti-HER3 antibody-drug conjugate. Specifically, the present disclosure relates to the use of an anti-HER3 antibody-drug conjugate in the preparation of a drug for treating EGFR-mutant tumors. The anti-HER3 antibody-drug conjugate has a structure as shown in formula I.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided are a heteroaryl compound, and a preparation method therefor and a use thereof in medicine. Specifically, provided are a heteroaryl compound as represented by general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, particularly a use thereof as a Bruton's tyrosine kinase (BTK) inhibitor and a use thereof for treating and/or preventing various diseases associated with excessive BTK activity, including cancer, autoimmune diseases, inflammatory diseases, allergic diseases, allergic reactions, respiratory diseases, cardiovascular diseases, viral infections, transplant rejection reactions, metabolic/endocrine disorders, and neurological disorders.
C07D 307/94 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
C07D 333/78 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present disclosure relates to a HER3/MET binding molecule and the pharmaceutical use thereof. Specifically, the present disclosure relates to an anti-HER3/MET bispecific antibody, an anti-HER3/MET antibody-drug conjugate, and a method therefor and the pharmaceutical use thereof for treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A pharmaceutical composition comprising a bispecific antibody specifically binding to GPRC5D and CD3. Specifically, the provided pharmaceutical composition comprises the bispecific antibody specifically binding to GPRC5D and CD3, and a buffer agent.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure relates to a macrocyclic compound and a use thereof. Specifically, the present disclosure provides a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R3, Z1-Z3, K1-K12, and X1-X3 are as defined in the description.
Provided are a CTLA4/TIGIT binding protein and the pharmaceutical use thereof. Specifically, the present invention relates to an anti-CTLA4/TIGIT antibody and a method for treating cancers and the pharmaceutical use thereof.
A fused heteroaryl compound represented by general formula (I), and a preparation method therefor and a pharmaceutical composition comprising the compound, and the use thereof as a therapeutic agent, in particular, the use thereof as a TLR7/8/9 inhibitor and the use thereof in the preparation of a drug for treating and/or preventing inflammatory and autoimmune diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
The present invention relates to a BTN3A-binding protein and medical uses thereof. Specifically, the present invention relates to the BTN3A-binding protein, a method thereof for activating γδ T cells and promoting cytokine release in γδ T cells, a method for treating cancer, and medical uses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are a 4-phenylpiperidine derivative and a use thereof. Specifically, provided are a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein functional groups are as defined in the description.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A heteroaryl compound, a preparation method therefor, and a use thereof in medicine. Specifically, provided are a heteroaryl compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, especially a use thereof as a PRMT5 inhibitor and a use thereof in treating and/or preventing cancer.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A preparation method for an SMTP-7 derivative and an intermediate thereof. The present disclosure relates to a preparation method for δ-deuterated-L-ornithine. The method achieves a high yield, has mild reaction conditions, and is suitable for industrial production.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
56.
ANTI-PSMA ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF
An anti-PSMA antibody-drug conjugate and the pharmaceutical use thereof. Specifically, disclosed is an anti-PSMA antibody-drug conjugate as represented by the general formula Pc-L-Y-D, wherein Pc is an anti-PSMA antibody or an antigen-binding fragment thereof, and L, Y and n are as defined in the description.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A pharmaceutical composition containing an antibody-drug conjugate of glucocorticoid. Specifically, the present invention relates to a pharmaceutical composition, comprising an antibody-drug conjugate and a counterion. The pharmaceutical composition has good aerodynamic characteristics and is suitable for inhalation administration.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61P 37/00 - Drugs for immunological or allergic disorders
58.
ANTIBODY-DRUG CONJUGATE TARGETING C-MET AND MEDICAL USE THEREOF
An antibody-drug conjugate targeting c-Met and the medical use thereof. The anti-c-Met antibody-drug conjugate has the structure as shown in formula (I): AB-(L-Y-D)n(I), wherein Ab is an anti-c-Met antibody, and L, Y and D are as defined in the description.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A preparation method for a KRAS G12D intermediate. Specifically, disclosed is a method for preparing a compound represented by formula (V-1). The preparation process is simple and can significantly reduce costs.
The present application relates to a fibroblast activation protein ligand and a use thereof, and in particular to a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and a use thereof in diagnosis or treatment of diseases related to a fibroblast activation protein, such as tumors or cancers.
A method for treating prostate cancer; specifically, the use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating metastatic castration-resistant prostate cancer.
The present disclosure relates to a benzofuran derivative and a preparation method for a benzofuran derivative intermediate. Specifically, the present disclosure relates to a preparation method for a primary amine compound, comprising the step of reacting a ketone compound with amino sulfonate in the presence of an acid catalyst to directly synthesize a primary amine compound. The method is high in yield, mild in reaction condition and suitable for industrial production.
C07B 43/04 - Formation or introduction of functional groups containing nitrogen of amino groups
C07C 209/58 - Preparation of compounds containing amino groups bound to a carbon skeleton by rearrangement reactions from or via amides
C07C 211/07 - Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present disclosure relates to a preparation method for formamide compounds. In particular, the present disclosure relates to a preparation method for compounds shown as formula 7a or pharmaceutically acceptable salts thereof. The preparation method has a high yield and is suitable for industrial production.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided are an anti-NPR1 antibody, a pharmaceutical composition comprising the antibody, and an immunoconjugate. Also provided are an isolated nucleic acid encoding the NPR1 antibody, a host cell comprising the isolated nucleic acid, a method for using the NPR1 antibody to detect an NPR1 peptide or a fragment thereof in a sample, and a method for using the NPR1 antibody, the pharmaceutical composition, and the immunoconjugate for treating, preventing or ameliorating diseases or conditions related to NPR1, the diseases or conditions related to NPR1 comprising hypertension.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A pharmaceutical composition comprising a cephalosporin antibacterial compound, which pharmaceutical composition comprises a compound as shown in formula (I), or a pharmaceutically acceptable salt thereof, and arginine. The composition has good stability and can be better used in clinical practice.
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 9/19 - Particulate form, e.g. powders lyophilised
The present disclosure relates to an amorphous substance and a crystal of a dioxopiperidine compound or a pharmaceutically acceptable salt thereof, a preparation method, and a use. Specifically, the present disclosure relates to an amorphous substance and a crystal of a compound shown in formula I or a pharmaceutically acceptable salt thereof, which have good physical and chemical properties.
The present disclosure relates to a drug-loaded macromolecule of an antifungal drug and a preparation method therefor. Specifically, the compound involved in the present disclosure is a dendritic polymer loaded with a drug and a pharmacokinetic modifier, and in particular relates to linking an antifungal drug to a dendritic polymer by means of a specific linker. The compound can be used for regulating the release speed of the antifungal drug, specifically by means of the selection of linker.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present disclosure relates to a ligand targeting a fibroblast activation protein, and particularly to a ligand represented by formula (I) and targeting a fibroblast activation protein, and a radioactive label thereof, wherein each substituent is defined in the description. The ligand can be used for imaging diseases or disorders related to the fibroblast activation protein, or treating the diseases or disorders related to the fibroblast activation protein.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
The present disclosure relates to a crystal form of a lipoprotein compound and a preparation method therefor. Specifically, the present disclosure provides a crystal form of (2S)-3-(3-{[(2-3-[(2S)-2-carboxyl-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)(3-[(2S)-2-carboxyl-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propionic acid and a preparation method therefor.
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 9/00 - Drugs for disorders of the cardiovascular system
70.
ANTI-TF ANTIBODY AND ANTI-TF ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF
The present invention relates to an anti-TF antibody and an anti-TF antibody-drug conjugate and a medical use thereof. Specifically, the present invention relates to an anti-TF antibody, and an anti-TF antibody-drug conjugate represented by general formula (Pc-L-Y-D), wherein the Pc is the anti-TF antibody, and L, Y, and n are as defined in the description.
An intermediate for preparing an oligonucleotide analog or a salt thereof, and a preparation method therefor. In particular, the present invention relates to a compound of formula VIII and a preparation method therefor. The definitions of substituents are as defined in the description.
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
The present disclosure relates to a crystalline form of a nitrogen-containing tetracyclic compound and a preparation method therefor. Specifically, provided in the present disclosure are a crystal form C, a crystal form F, a crystal form G, a crystal form H, a crystal form L, a crystal form M, a crystal form N, a crystal form R and a crystal form S of (S)-4-((S)-10-acryloyl-4-chloro-2-fluoro-14-oxo-8,8a,9,10,11,12-hexahydro-7H,14H-pyrazino[1',2':5,6][1,5]diazocin[3,2,1-hi]indazol-3-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (formula 1), which crystal forms have good stability and can be better used in clinical treatment.
C07D 487/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains three hetero rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
The present invention relates to an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof. Specifically, the present invention relates to an anti-MUC1 antibody or an antigen binding fragment thereof, an anti-EGFR antibody or an antigen binding fragment thereof, an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
74.
FUSED TETRACYCLIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE
The present disclosure relates to a fused tetracyclic compound and a preparation method therefor and a use thereof in medicine. Specifically, the present disclosure relates to a fused tetracyclic compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and a use thereof as a therapeutic agent, particularly a use thereof in the preparation of a drug for inhibiting KRAS G12D. The groups in general formula (I) are as defined in the description.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The present disclosure relates to a use of an anti-TROP2 antibody combined with a TROP2-targeting drug in treating cancer. Specifically, the present disclosure relates to a use of an anti-TROP2 antibody in the preparation of a drug for preventing, alleviating or eliminating adverse reactions caused by a TROP2-targeting drug in a subject, a use of an anti-TROP2 antibody combined with a TROP2-targeting drug in the preparation of a drug for treating a tumor, a method for preventing, alleviating or eliminating adverse reactions caused by a TROP2-targeting drug in a subject, a method for treating a tumor, a drug packaging box, and a pharmaceutical composition.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to a method for preparing an indolizino[1,2-b]quinoline-10,13-dione derivative. Specifically, the present disclosure relates to a method for preparing a compound of formula I. The method comprises the step of using a compound of formula D-a to form the compound of formula I under acidic conditions. The method can efficiently achieve the enrichment of the compound of formula I and increase process yield, and is suitable for industrial production.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
79.
FAP/4-1BB/CD40 BINDING MOLECULE AND MEDICINAL USE THEREOF
The present disclosure relates to an FAP/4-1BB/CD40 binding molecule and a medicinal use thereof. Specifically, the present disclosure relates to an FAP/4-1BB/CD40 binding molecule, a 4-1BB binding molecule, a polynucleotide encoding a binding molecule, a vector, a pharmaceutical composition, a method for using same for treatment of cancer, and a related pharmaceutical use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an anti-DLL3 antibody, and an antibody-drug conjugate and pharmaceutical use thereof. The present invention specifically relates to an anti-DLL3 antibody-exatecan drug conjugate represented by general formula Pc-L-Y-D, wherein Pc is an anti-DLL3 antibody, and L, Y and n are as defined in the description.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure relates to an IL-36R binding protein and a medicinal use thereof. Specifically, the present disclosure relates to an IL-36R/IL-23 binding protein, an IL-36R binding protein, a method for treating inflammatory diseases and autoimmune diseases, and a related pharmaceutical use.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present disclosure relates to a crystalline form of a sulfonamide derivative and a preparation method therefor. Specifically, the present disclosure provides a new crystalline form of a compound as represented by formula (1) and a preparation method therefor.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present disclosure relates to a method for preparing tetrahydro-1-naphthylamine and derivatives thereof. Specifically, the present disclosure relates to a method for preparing (1S,4S)-4-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine, and the method comprises the step of reacting compound C-1 under the condition of (R)-2-methyl-CBS-oxazaborolidine so as to form compound D-1. The method is simple to operate and is suitable for industrial production.
C07C 13/18 - Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a six-membered ring with a cyclohexane ring
C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
84.
SUBSTITUTED AMINOPYRIMIDINE MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF
The present disclosure relates to substituted aminopyrimidine macrocyclic compounds, a preparation method therefor, and the medical uses thereof. Particularly, the present disclosure relates to substituted aminopyrimidine macrocyclic compounds represented by general formula (I), a preparation method therefor, pharmaceutical compositions containing the compounds, the use thereof as therapeutic agents, particularly the use as EGFR inhibitors, and the use thereof in the preparation of drugs used for treating and/or preventing EGFR-mediated or EGFR-dependent diseases or disorders.
C07D 239/70 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present disclosure relates to a pharmaceutically acceptable salt and a crystal form of a triazole compound, and a preparation method therefor. Specifically, provided in the present disclosure are a pharmaceutically acceptable salt and a crystal form of the compound (1S,3aS,5S,6aR)-5-((6-(5-(((4-(methoxymethyl)pyrimidin-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)-2-methylpyridin-3-yl)oxy)octahydrocyclopentadien-1-carboxylic acid of formula I, and a preparation method therefor. The corresponding salt has a good stability and can be better used in clinical treatment.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present disclosure relates to a pharmaceutical composition containing an Eribulin derivative drug conjugate. Specifically, the present disclosure relates to a pharmaceutical composition, comprising an antibody-drug conjugate and a buffering agent. The antibody-drug conjugate has a structure as shown in Formula I, wherein Ab is Pertuzumab. The pharmaceutical composition of the present disclosure has good stability.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
Use of an anti-HER2 antibody-drug conjugate in the preparation of a drug for treating HER2 low-expression breast cancer. The structure of the antibody-drug conjugate is represented by formula (I).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure relates to tyrosinase-mediated protein site-specific conjugation and a use thereof. Specifically, the present disclosure provides tyrosinase-mediated protein site-specific conjugation and a use thereof in the preparation of a drug (for example, an ADC).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A method for treating asthma by using a TSLP antibody. An antibody or antigen-binding fragment thereof specific to thymic stromal lymphopoietin (TSLP) is used to treat asthma and/or reduce asthma aggravation frequency and/or severity, and/or reduce the annualised asthma exacerbation rate, and/or reduce ACQ-6 scores in subjects.
The present invention relates to an anti-CD40 antibody-drug conjugate, a preparation method therefor and a medical use thereof, and in particular to an antibody-drug conjugate comprising an anti-CD40 antibody or an antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and a method thereof for treating an autoimmune disease, a graft-versus-host disease and/or a graft rejection reaction, and a related pharmaceutical use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 37/00 - Drugs for immunological or allergic disorders
91.
COMPOSITION OF CD40-BINDING MOLECULE AND PHARMACEUTICAL USE THEREOF
A composition of a CD40-binding molecule and pharmaceutical use thereof. Specifically, the composition comprises an anti-CD40 antibody or an antigen-binding fragment thereof or an antibody-drug conjugate and a buffer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/00 - Drugs for immunological or allergic disorders
92.
CRYSTAL FORM OF KRAS G12D INHIBITOR AND PREPARATION METHOD THEREFOR
The present disclosure relates to a crystal form of a KRAS G12D inhibitor and a preparation method therefor. Specifically, provided in the present disclosure are crystal forms A, B, C, D, E, F, G, H, I, J, K, L, M, N and O of a compound as represented by formula (I), and a preparation method therefor.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The present disclosure provides a phosphate ester prodrug of a Malt1 inhibitor. Specifically, the present disclosure provides a prodrug as represented by formula (I) or a pharmaceutically acceptable salt thereof and a use thereof in preparation of a drug.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
The present invention relates to an anti-HER3 antibody-drug conjugate composition and pharmaceutical use thereof. Specifically, the composition of the present invention comprises an anti-HER3 antibody-drug conjugate and a buffering agent.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure relates to a CLDN18.2/4-1BB binding protein and a medical use thereof. Specifically, the present disclosure relates to a CLDN18.2/4-1BB binding protein, a 4-1BB binding protein, a CD16A binding protein, methods for treating cancer by using same, and related pharmaceutical uses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to a crystalline form of a pharmaceutically acceptable salt of a pyrazolo heteroaryl derivative. Specifically, the present disclosure relates to a crystalline form of a pharmaceutically acceptable salt of a compound represented by formula (I). The new crystal form of the present disclosure has good physicochemical properties.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The present disclosure relates to a pharmaceutically acceptable salt of a nitrogen-containing heterocyclic compound, a crystal form thereof, and a preparation method therefor. Specifically, the present disclosure provides a pharmaceutically acceptable salt of a formula 1 compound (R)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyrido[3,2-e][1,4]oxazepine-9-formamide, and a crystal form thereof, and a preparation method therefor, and the corresponding salt has good stability and can be better utilized in clinical treatment.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure relates to a pharmaceutically acceptable salt of a quinoline amine compound, and a crystal form thereof and a preparation method therefor. Specifically, provided in the present disclosure are a pharmaceutically acceptable salt of 8-chloro-N-(2,2-difluorobenzo[d][1,3]dioxolane-5-yl)quinolin-2-amine, and a crystal form thereof and a preparation method therefor. The corresponding salt has good stability and can be better used in clinical treatment.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
99.
ANTI-LIV-1 ANTIBODY, DRUG CONJUGATE THEREOF, AND MEDICAL USE THEREOF
Provided are a LIV-1 binding molecule and a preparation method therefor, and a corresponding immunoconjugate, a pharmaceutical composition, a medical use, and a method for preventing a disease, in particular a method for treating cancer or a tumor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure relates to a pharmaceutical composition comprising a bispecific antibody specifically binding to HGFR and EGFR. Specifically, the present disclosure relates to a pharmaceutical composition comprising a bispecific antibody specifically binding to HGFR and EGFR, and a use thereof as a drug.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
patents